TMDX
HealthcareTransMedics Group, Inc.
$126.28
+$3.59 (+2.93%)
Jan 5, 2026
Price History (1Y)
Analysis
TransMedics Group, Inc. is a healthcare company operating within the medical devices industry. The company has a significant market presence, with a market capitalization of $4.32 billion and revenue of $566.35 million (TTM). In terms of scale, TransMedics employs 728 individuals. The company's financial health indicates solid profitability margins, with gross margin at 60.3%, operating margin at 16.2%, and profit margin also at 16.2%. Returns on equity and assets are substantial, standing at 32.5% and 6.9%, respectively. The balance sheet shows a relatively high debt-to-equity ratio of 146.21, although this is offset by a significant cash position of $466.17 million. TransMedics' valuation context is notable for its relatively high P/E ratio of 48.38 (TTM) and forward P/E of 43.34. The company's growth rates are substantial, with revenue growth at 32.2% (YoY) and earnings growth at a significant 450.1%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $4.32B
- P/E Ratio
- 48.38
- 52-Week High
- $156.00
- 52-Week Low
- $55.00
- Avg Volume
- 866.64K
- Beta
- 2.02
Company Info
- Industry
- Medical Devices
- Exchange
- NGM
- Country
- United States
- Employees
- 728